Odyssey Group International Announces Upcoming Television Appearance by Brett Favre and Dr. Jake VanLandingham on NewsNation Now’s “The Donlon Report”

Rhea-AI Summary

Odyssey Group International, Inc. (OTCQB:ODYY) announced that Dr. Jake VanLandingham will appear on NewsNation Now's 'The Donlon Report' with Brett Favre to discuss PRV-002, a novel treatment for concussions. The segment airs at 7:30 PM ET on March 10, 2021. Dr. VanLandingham expressed enthusiasm over the media attention PRV-002 is receiving as the company gears up for human clinical trials. PRV-002, a synthetic neurosteroid, shows promise in preclinical studies, demonstrating neuroprotective effects that could benefit those suffering from mild traumatic brain injury.

Positive

• Dr. Jake VanLandingham's appearance on major media highlights growing awareness of PRV-002.
• PRV-002 shows promise in preclinical studies, demonstrating potential neuroprotective effects.

Negative

• None.

IRVINE, CA / ACCESSWIRE / March 10, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Dr. Jake VanLandingham, Odyssey's Vice President of Drug Development and the lead scientist developing PRV-002 will be joining Brett Favre to discuss the impact of concussions and the importance of this novel concussion treatment on NewsNation Now's "The Donlon Report." The segment is expected to air at 7:30PM Eastern Time on March 10, 2021.

"I am pleased that PRV-002, our pre-clinical stage concussion treatment continues to receive so much attention from the media," said Dr. Jake VanLandingham. "We look forward to continuing development of the drug through the initiation of our upcoming human clinical trials."

Dr. VanLandingham has appeared alongside Brett Favre on numerous media segments to discuss the impact of concussion and the development of PRV-002 including:

• CheddarTV's "Closing Bell" on Friday, February 5 (watch online)
• Newsmax's "National Report" on Sunday, February 7 (watch online) and
• Fox Business' "Kennedy Nation" on Monday February 8 (watch online)

In addition, former NFL stars Kurt Warner and Mark Rypien discussed PRV-002 on Fox News' "Fox and Friends" on Saturday, February 6 (watch online).

Odyssey acquired PRV-002 via an all-stock transaction that closed March 2, 2021.

About Odyssey Group International, Inc.

Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.

For more information, visit http://www.odysseygi.com.

About PRV-002

PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

Media and Investors Contacts:

CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital

SOURCE: Odyssey Group International Inc.

View source version on accesswire.com:
https://www.accesswire.com/634545/Odyssey-Group-International-Announces-Upcoming-Television-Appearance-by-Brett-Favre-and-Dr-Jake-VanLandingham-on-NewsNation-Nows-The-Donlon-Report

FAQ

What is PRV-002 being developed for?

PRV-002 is being developed for the treatment of mild traumatic brain injury (concussion).

When will Dr. Jake VanLandingham appear on NewsNation?

Dr. Jake VanLandingham will appear on NewsNation's 'The Donlon Report' on March 10, 2021, at 7:30 PM ET.

What has been the media response to PRV-002?

PRV-002 has received significant media attention, with multiple appearances by Dr. VanLandingham and discussions about its potential impact.

What is the stock symbol for Odyssey Group International?

The stock symbol for Odyssey Group International is ODYY.

What is the current status of PRV-002 development?

PRV-002 is currently in the preclinical stage, with upcoming plans for human clinical trials.